LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
LakeShore Biopharma (NASDAQ: LSB), a global biopharmaceutical company, has announced key developments in evaluating a non-binding proposal received on August 26, 2025. The company's independent special committee has appointed Kroll, LLC as financial advisor, along with Gibson, Dunn & Crutcher LLP as U.S. legal counsel and Maples and Calder as Cayman Islands legal counsel.
The Special Committee continues to evaluate the proposal, with no decisions made yet. The company emphasized there is no guarantee of a definitive offer, agreement execution, or transaction approval.
LakeShore Biopharma (NASDAQ: LSB), azienda biofarmaceutica globale, ha comunicato aggiornamenti rilevanti riguardo alla valutazione di una proposta non vincolante ricevuta il 26 agosto 2025. Il comitato speciale indipendente ha nominato Kroll, LLC come consulente finanziario, Gibson, Dunn & Crutcher LLP come consulente legale negli Stati Uniti e Maples and Calder come consulente legale nelle Isole Cayman.
Il Comitato Speciale sta proseguendo la valutazione della proposta e non ha ancora preso decisioni definitive. La società ha sottolineato che non vi è alcuna garanzia che venga formulata un’offerta definitiva, che venga sottoscritto un accordo o che la transazione venga approvata.
LakeShore Biopharma (NASDAQ: LSB), una compañía biofarmacéutica global, ha anunciado avances importantes en la evaluación de una propuesta no vinculante recibida el 26 de agosto de 2025. El comité especial independiente designó a Kroll, LLC como asesor financiero, a Gibson, Dunn & Crutcher LLP como abogado en EE. UU. y a Maples and Calder como asesor legal en las Islas Caimán.
El Comité Especial continúa analizando la propuesta y aún no ha tomado decisiones. La compañía destacó que no hay garantía de que se presente una oferta definitiva, se firme un acuerdo o se apruebe una transacción.
LakeShore Biopharma (NASDAQ: LSB)는 글로벌 바이오제약사로서 2025년 8월 26일 접수된 비구속적 제안서에 대한 평가와 관련된 주요 진행 상황을 발표했습니다. 독립 특별위원회는 재무 자문사로 Kroll, LLC를, 미국 법률 자문으로 Gibson, Dunn & Crutcher LLP를, 케이맨제도 법률 자문으로 Maples and Calder를 선임했습니다.
특별위원회는 제안서에 대한 검토를 계속하고 있으며 아직 결정은 내려지지 않았습니다. 회사는 확정적인 제안서 제출, 계약 체결 또는 거래 승인에 대한 보장은 없다고 강조했습니다.
LakeShore Biopharma (NASDAQ: LSB), une société biopharmaceutique mondiale, a annoncé des développements majeurs concernant l'évaluation d'une proposition non contraignante reçue le 26 août 2025. Le comité spécial indépendant a nommé Kroll, LLC comme conseiller financier, Gibson, Dunn & Crutcher LLP comme conseil juridique aux États-Unis et Maples and Calder comme conseil juridique aux îles Caïmans.
Le comité spécial poursuit l'examen de la proposition et n'a pris aucune décision définitive à ce stade. La société a souligné qu'il n'y a aucune garantie qu'une offre définitive soit faite, qu'un accord soit conclu ou qu'une transaction soit approuvée.
LakeShore Biopharma (NASDAQ: LSB), ein globales Biopharma-Unternehmen, hat wichtige Entwicklungen bei der Prüfung eines am 26. August 2025 eingegangenen unverbindlichen Angebots bekannt gegeben. Das unabhängige Sonderkomitee hat Kroll, LLC als Finanzberater sowie Gibson, Dunn & Crutcher LLP als US-Rechtsberater und Maples and Calder als Rechtsberater für die Kaimaninseln bestellt.
Das Sonderkomitee setzt die Prüfung des Vorschlags fort; endgültige Entscheidungen wurden noch nicht getroffen. Das Unternehmen betonte, dass es keine Garantie für ein verbindliches Angebot, den Abschluss einer Vereinbarung oder die Genehmigung einer Transaktion gibt.
- Appointment of reputable advisors indicates serious consideration of the proposal
- Multiple expert firms engaged to ensure comprehensive evaluation
- No guarantee of a definitive agreement or transaction completion
- Uncertainty regarding the final outcome of the proposal evaluation
The Special Committee is continuing its review and evaluation of the Proposal. The Board cautions the Company's shareholders and others considering trading the Company's securities that no decisions have been made with respect to the Proposal. There can be no assurance that any definitive offer will be received, that any definitive agreement will be executed relating to the transaction contemplated by the Proposal, or that the transaction contemplated by the Proposal or any other similar transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to any transaction, except as required under applicable law.
About LakeShore Biopharma
LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Influenza, and other virus infections. The Company operates in
Cautionary Statement Regarding Forward-Looking Statements
This announcement contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the
View original content:https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-appointment-of-independent-financial-advisor-and-legal-counsel-to-the-special-committee-302552480.html
SOURCE LakeShore Biopharma Co., Ltd.
FAQ
What advisors has LakeShore Biopharma (LSB) appointed to evaluate the August 2025 proposal?
When did LakeShore Biopharma receive the preliminary non-binding proposal?
What is the current status of LSB's proposal evaluation process?
What type of company is LakeShore Biopharma (LSB)?
